Nile Pharmaceuticals results, Fiscal year 2023
Net profit, assets, equity and cash flow for Fiscal year 2023, against the same period a year earlier, from the published financial statements. fiscal year starts in July.
Net profit119 millionEGP · +32.9% vs the same period a year earlier
Total assets1.04 billionEGP · +35.0% vs the same period a year earlier
Shareholders' equity478 millionEGP · +11.1% vs the same period a year earlier
Operating cash flow-256 millionEGP · −5323.0% vs the same period a year earlier
In short
- Nile Pharmaceuticals's net profit for Fiscal year 2023 was about 119 million EGP, up +32.9% from 89.67 million EGP in Fiscal year 2022.
- Total assets at the end of Fiscal year 2023 were about 1.04 billion EGP, and shareholders' equity about 478 million EGP.
- Operating cash flow for Fiscal year 2023 was negative at 256 million EGP.
Key lines against the same period a year earlier
This periodFiscal year 2022Change
Net profit119 million89.67 million+32.9%
Gross profit595 million535 million+11.1%
Total assets1.04 billion769 million+35.0%
Total liabilities560 million339 million+65.4%
Shareholders' equity478 million431 million+11.1%
Total liabilities and equity1.04 billion769 million+35.0%
Operating cash flow-256 million4.91 million−5323.0%
Investing cash flow-27.52 million-48 million+42.7%
Financing cash flow273 million-12.62 million+2260.1%
Net change in cash-11.38 million-55.71 million+79.6%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version.
Nile Pharmaceuticals's Q1 2027 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy